-- 奧羅賓多製藥（Aurobindo Pharma，NSE：AUROPHARMA，BOM：524804）位於印度特倫甘納邦馬哈布布納加爾地區的口服固體製劑生產廠接受美國食品藥品監督管理局（FDA）檢查後，FDA發出了一份「建議採取自願行動」的通知。 根據週三提交給印度證券交易所的文件，此次檢查於1月28日至2月10日進行，FDA出具了一份包含九項觀察結果的「483表格」。 此次檢查已結束。 該公司股價在近期交易中上漲超過3%。
Related Articles
Asia
New Asia Construction Logs About NT$57 Million in Q1 Profit
New Asia Construction and Development (TPE:2516) posted a profit attributable to owners of NT$56.5 million, or NT$0.25 per share, for the first quarter, according to a Tuesday filing with the Taiwan Stock Exchange.Shares gained over 1% in Wednesday's midday trade.Meanwhile, operating revenue stood at NT$1.62 billion.The construction company did not provide comparative year-ago figures.
$TPE:2516
Asia
Hsin Kuang Steel Logs Nearly NT$71 Million in Q1 Profit; Shares Drop 3%
Hsin Kuang Steel (TPE:2031) posted a profit attributable to owners of NT$70.7 million, or NT$0.22 per share, for the first quarter, according to a Tuesday filing with the Taiwan Stock Exchange.Shares slid over 3% in Wednesday's midday trade.Meanwhile, operating revenue stood at NT$4.59 billion.The steel manufacturer did not provide comparative year-ago figures.
$TPE:2031
Asia
Inspace Creation to Debut on ACE Market of Bursa Malaysia
Inspace Creation (KLSE:INSPACE) is slated to list on the ACE Market on Friday, May 8, according to a Tuesday Malaysian bourse filing.The interior fitting-out specialist will mark its entry into Bursa Malaysia's construction sector under the stock name INSPACE, and stock code 0451.Upon listing, the company's enlarged issued share capital will stand at 369.3 million shares, with a total value of 24.7 million ringgit.The stock will trade under code 0451. The group confirmed no additional or new classes of securities will be issued alongside the IPO.
$KLSE:INSPACE